tumor might still lead to survival benefits for highly selected patients with metastases. The importance of stratification according to age and sex has been suggested in other studies, 4 , 5 but it has never been applied to a sufficiently large sample
Search Results
Marina Deuker, Giuseppe Rosiello, Lara Franziska Stolzenbach, Thomas Martin, Claudia Collà Ruvolo, Luigi Nocera, Zhe Tian, Frederik C. Roos, Andreas Becker, Luis A. Kluth, Derya Tilki, Shahrokh F. Shariat, Fred Saad, Felix K.H. Chun, and Pierre I. Karakiewicz
Priscilla K. Brastianos, William T. Curry, and Kevin S. Oh
Background An estimated 8% to 10% of patients with cancer will develop symptomatic brain metastases. 1 , 2 The geographic distribution of metastases reflects the volume of brain parenchyma and vascular flow: approximately 80% within cerebral
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen
Background More than one-third of patients with metastatic non–small cell lung cancer (mNSCLC) will develop bone metastases during the course of their illness. 1 Development of bone metastases often leads to significant morbidity, with
Fabian M. Johnston, Michael N. Mavros, Joseph M. Herman, and Timothy M. Pawlik
Traditionally, local therapy for hepatic metastases has been largely reserved for patients with colorectal liver metastases (CRLM) or, less often, neuroendocrine liver metastases (NELM). Colorectal cancer is one of the most common types of cancer
Kazuki Sudo, Xuemei Wang, Lianchun Xiao, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, David C. Rice, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Adarsh Hiremath, Nikolaos Charalampakis, Ritsuko Komaki, Mariela A. Blum, Stephen G. Swisher, Dipen M. Maru, Heath D. Skinner, Jeana L. Garris, Jane E. Rogers, Wayne L. Hofstetter, and Jaffer A. Ajani
Background Among patients with localized esophageal cancer (LEC), 35% or more develop distant metastases (DM) as first relapse, most in the first 24 months after local therapy. 1 Worldwide, yearly new cases of esophageal cancer are estimated
Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza
adjuvant setting of breast cancer might have any effect on the natural course of the disease. Most specifically, they investigated for any beneficial effects on overall survival, prevention of disease recurrences, and occurrence of bone metastases
Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss
Background Brain metastases are a critical site of disease progression in patients with metastatic renal cell carcinoma (mRCC). Large institutional and population-based studies estimate the incidence of brain metastasis to be 5% to 20%, 1
Nancy Kemeny
arterial infusion (HAI) for the treatment of liver only metastases. I believe 3 circumstances exist in which HAI therapy may be considered. The first is after liver resection. Four randomized controlled trials address the use of HAI therapy after hepatic
Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey
Background Approximately 15% of patients with colorectal cancer (CRC) have synchronous colorectal liver metastases (CLM; detected at initial diagnosis or during treatment after initial diagnosis), and approximately 30% of patients with CRC have
Sajeel Chowdhary and Marc Chamberlain
The authors have no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1 Kaplan JG DeSouza TG Farkash A . Leptomeningeal metastases
